Suppr超能文献

系统预刺激和鼻内加强免疫 BcfA 佐剂无细胞百日咳疫苗可产生 CD4+IL-17+鼻组织固有 T 细胞,并减少鼻定植。

Systemic priming and intranasal booster with a BcfA-adjuvanted acellular pertussis vaccine generates CD4+ IL-17+ nasal tissue resident T cells and reduces nasal colonization.

机构信息

Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, United States.

Department of Chemical Engineering, University of Texas-Austin, Austin, TX, United States.

出版信息

Front Immunol. 2023 May 18;14:1181876. doi: 10.3389/fimmu.2023.1181876. eCollection 2023.

Abstract

INTRODUCTION

Resurgence of pertussis, caused by Bordetella pertussis, necessitates novel vaccines and vaccination strategies to combat this disease. Alum-adjuvanted acellular pertussis vaccines (aPV) delivered intramuscularly reduce bacterial numbers in the lungs of immunized animals and humans, but do not reduce nasal colonization. Thus, aPV-immunized individuals are sources of community transmission. We showed previously that modification of a commercial aPV (Boostrix) by addition of the Th1/17 polarizing adjuvant Bordetella Colonization Factor A (BcfA) attenuated Th2 responses elicited by alum and accelerated clearance of B. pertussis from mouse lungs. Here we tested whether a heterologous immunization strategy with systemic priming and mucosal booster (prime-pull) would reduce nasal colonization.

METHODS

Adult male and female mice were immunized intramuscularly (i.m.) with aPV or aPV/BcfA and boosted either i.m. or intranasally (i.n.) with the same formulation. Tissue-resident memory (TRM) responses in the respiratory tract were quantified by flow cytometry, and mucosal and systemic antibodies were quantified by ELISA. Immunized and naïve mice were challenged i.n. with Bordetella pertussis and bacterial load in the nose and lungs enumerated at days 1-14 post-challenge.

RESULTS

We show that prime-pull immunization with Boostrix plus BcfA (aPV/BcfA) generated IFNγ+ and IL-17+ CD4+ lung resident memory T cells (TRM), and CD4+IL-17+ TRM in the nose. In contrast, aPV alone delivered by the same route generated IL-5+ CD4+ resident memory T cells in the lungs and nose. Importantly, nasal colonization was only reduced in mice immunized with aPV/BcfA by the prime-pull regimen.

CONCLUSIONS

These results suggest that TH17 polarized TRM generated by aPV/BcfA may reduce nasal colonization thereby preventing pertussis transmission and subsequent resurgence.

摘要

简介

由百日咳博德特氏菌引起的百日咳卷土重来,需要新型疫苗和接种策略来对抗这种疾病。肌肉内注射含铝佐剂的无细胞百日咳疫苗(aPV)可减少免疫动物和人类肺部的细菌数量,但不能减少鼻定植。因此,aPV 免疫个体是社区传播的来源。我们之前曾表明,通过添加 Th1/17 极化佐剂百日咳定植因子 A(BcfA)来修饰商业 aPV(Boostrix),可以减弱铝佐剂引起的 Th2 反应,并加速从小鼠肺部清除百日咳博德特氏菌。在这里,我们测试了用系统的初免和粘膜加强(初免-加强)的异源免疫策略是否会减少鼻定植。

方法

成年雄性和雌性小鼠肌肉内(i.m.)接种 aPV 或 aPV/BcfA,并以相同的制剂肌肉内或鼻腔内(i.n.)加强。通过流式细胞术定量呼吸道组织驻留记忆(TRM)反应,并通过 ELISA 定量粘膜和系统抗体。用博德特氏菌百日咳挑战免疫和未免疫的小鼠,在挑战后第 1-14 天计数鼻和肺中的细菌负荷。

结果

我们表明,用 Boostrix 加 BcfA(aPV/BcfA)进行初免-加强免疫会在肺部产生 IFNγ+和 IL-17+ CD4+ 肺驻留记忆 T 细胞(TRM),并在鼻内产生 CD4+IL-17+ TRM。相比之下,通过相同途径单独接种 aPV 会在肺部和鼻腔内产生 IL-5+ CD4+ 驻留记忆 T 细胞。重要的是,只有用 aPV/BcfA 进行初免-加强免疫的小鼠,鼻腔定植才会减少。

结论

这些结果表明,aPV/BcfA 产生的 TH17 极化 TRM 可能会减少鼻定植,从而防止百日咳传播和随后的复发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a222/10232778/cd1b9feb97e1/fimmu-14-1181876-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验